Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation

JACC Cardiovasc Interv. 2017 Apr 24;10(8):786-795. doi: 10.1016/j.jcin.2016.12.020.

Abstract

Objectives: This study investigated the vasomotor response to nitroglycerine (NTG) up to 5 years after ABSORB implantation.

Background: There are no data regarding long-term vasomotor response after everolimus-eluting bioresorbable vascular scaffold ABSORB implantation.

Methods: We performed quantitative coronary angiography of the scaffolded and proximal and distal adjacent segments of patients from ABSORB Cohort B study before and after 200 μg of intracoronary NTG at 2, 3, and 5 years of follow-up. The mean changes of maximal and mean lumen diameters in the scaffolded and adjacent segments were calculated.

Results: The mean in-scaffold lumen diameter change in response to NTG showed a trend to increase over time with absolute values of 0.03 ± 0.09 mm, 0.05 ± 0.12 mm, and 0.07 ± 0.08 mm at 2, 3, and 5 years, respectively (p = 0.40). The maximal in-scaffold lumen diameter change significantly increased with values of 0.03 ± 0.14 mm, 0.06 ± 0.16 mm, and 0.11 ± 0.1 mm at 2, 3, and 5 years, respectively (p = 0.03). The normalized mean lumen diameter change after NTG in the scaffold relative to the adjacent segments was 51.9 ± 54.8% at 5 years of follow-up (p = 0.60).

Conclusions: Although there was a numerical increase of the vasomotor response to NTG after ABSORB implantation measured by quantitative coronary angiography with mean lumen diameter, the change was not statistically significant. However, the maximal lumen diameter changes increased over time from 2 to 5 years and attained statistical significance. The vasomotor response to NTG after ABSORB implantation moderately trended to increase, which is consistent with the progressive degradation and bioresorption of the scaffold, but the degree of vasomotor response remained lower in comparison with adjacent segments.

Keywords: ABSORB; bioresorbable scaffold; vasomotion.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Absorbable Implants*
  • Cardiovascular Agents / administration & dosage*
  • Cardiovascular Agents / adverse effects
  • Coated Materials, Biocompatible*
  • Coronary Angiography
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / physiopathology
  • Coronary Artery Disease / therapy*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / drug effects*
  • Coronary Vessels / physiopathology
  • Everolimus / administration & dosage*
  • Everolimus / adverse effects
  • Humans
  • Nitroglycerin / administration & dosage*
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Interventional
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects*
  • Vasodilator Agents / administration & dosage*
  • Vasomotor System / drug effects*
  • Vasomotor System / physiopathology

Substances

  • Cardiovascular Agents
  • Coated Materials, Biocompatible
  • Vasodilator Agents
  • Everolimus
  • Nitroglycerin